Study Shows Product Is Effective in Significantly Reducing Elevated Total
Blood Cholesterol Levels
CHESTERFIELD, Mo., Jan. 12 /PRNewswire-FirstCall/ -- Reliv International,
Inc. (Nasdaq: RELV), an international manufacturer and network marketer of
nutritional supplements and food products, announced the release of results of
an independent clinical trial on a dietary supplement newly developed by Reliv
scientists.
The clinical trial was conducted under the direction of Joe Vinson, Ph.D.,
a Professor of Chemistry at the University of Scranton. Dr. Vinson has over
25 years of research and clinical experience with dietary supplements. The
study sought to determine whether long-term supplementation with the use of
Reliv's new formulation would have an influence on plasma lipids in subjects
with elevated cholesterol levels, in a double-blind, placebo crossover design.
The results of the trial showed statistically significant decreases in
participants' bad cholesterol (LDL) and triglyceride levels, decreases in the
cholesterol/good cholesterol (HDL) ratio and decreases in the bad to good
(LDL/HDL) ratios. Subjects participating in the trial initially were
identified as having undesirable cholesterol ratios but, after a period of
supplementation with the Reliv formulation, had achieved desirable levels. In
addition, the trial results also showed improvement in cholesterol levels for
those participants who were already taking statin (cholesterol-reducing)
drugs.
The summary report on the clinical trial states that the overall effect of
the program for participants in the study was a significant reduction in the
10-year risk of developing cardiovascular disease.
"Almost 700,000 people die annually in the United States from heart
disease," reported Dr. Carl W. Hastings, Vice President for Research and
Development of Reliv, who participated in development of the Reliv
formulation. "Heart disease is the number one cause of death in the United
States and diagnosed heart disease occurs in 11% of non-institutionalized
adults. High blood cholesterol is a major risk factor for coronary heart
disease," he said. "Our goal in developing this new formulation has been to
address the serious health risks caused by elevated cholesterol levels in such
a high proportion of our population."
"The clinical trial on this new formulation has established not only its
efficacy but also included testing which establishes the safety of the
formulation for use by the participants," reported David Barnes, Vice
President Technical Affairs and Manufacturing Operations.
Reliv plans to introduce the new product at its Phoenix Leadership
Conference on February 5, 2005.
Reliv distributes its products exclusively through its network of
independent distributors in the United States and 9 other countries.
NOTE: Any statement released by Reliv International, Inc. that is forward
looking is made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Editors and investors are cautioned
that forward-looking statements involve risk and uncertainties that may affect
the Company's business prospects and performance. This includes economic,
competitive, governmental, technological and other factors discussed in the
Company's filings with the SEC on forms 10-K and 10-Q.
SOURCE Reliv International, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/103123.html
CONTACT:
David G. Kreher, Chief Financial Officer,
+1-636-537-9715, or Fred Nielson, Investor Relations,
+1-636-537-9715, both of Reliv International, Inc., or Al Palombo
of Cameron Associates, +1-212-554-5488
|
